Clearside Biomedical (NASDAQ:CLSD) announced its quarterly earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.13), Morningstar.com reports. The company had revenue of $0.03 million during the quarter.
Shares of CLSD stock opened at $1.37 on Thursday. Clearside Biomedical has a 52 week low of $0.99 and a 52 week high of $15.33. The firm has a market capitalization of $44.83 million, a P/E ratio of -0.51 and a beta of -1.13. The company has a quick ratio of 4.59, a current ratio of 4.59 and a debt-to-equity ratio of 0.22.
A number of hedge funds have recently made changes to their positions in CLSD. Alps Advisors Inc. lifted its position in Clearside Biomedical by 22.3% during the third quarter. Alps Advisors Inc. now owns 56,670 shares of the company’s stock valued at $349,000 after buying an additional 10,315 shares during the period. Rhumbline Advisers lifted its position in Clearside Biomedical by 48.5% during the fourth quarter. Rhumbline Advisers now owns 36,979 shares of the company’s stock valued at $40,000 after buying an additional 12,076 shares during the period. Geode Capital Management LLC lifted its position in Clearside Biomedical by 4.9% during the fourth quarter. Geode Capital Management LLC now owns 303,512 shares of the company’s stock valued at $324,000 after buying an additional 14,181 shares during the period. Bank of America Corp DE lifted its position in Clearside Biomedical by 915.6% during the second quarter. Bank of America Corp DE now owns 16,574 shares of the company’s stock valued at $177,000 after buying an additional 14,942 shares during the period. Finally, Marshall Wace North America L.P. lifted its position in Clearside Biomedical by 2.8% during the third quarter. Marshall Wace North America L.P. now owns 582,625 shares of the company’s stock valued at $3,583,000 after buying an additional 15,916 shares during the period. 39.93% of the stock is owned by institutional investors.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.
See Also: Special Dividends
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.